Drug intelligence / Profile preview

TXP1-oligo2

Development stage: Preclinical
Lead developer: Ossianix
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

TXP1-oligo2 is a preclinical oligonucleotide-antibody conjugate being developed by Ossianix. It utilizes the company's TXP1 brain shuttle platform, which consists of a single-domain VNAR (variable new antigen receptor) antibody derived from sharks. This shuttle targets the transferrin receptor 1 (TfR1) to facilitate transport across the blood-brain barrier (BBB) via receptor-mediated transcytosis, enabling the delivery of the oligonucleotide payload into the central nervous system (CNS). While the TXP1 shuttle mechanism is well-defined, the specific molecular target of the oligonucleotide and the intended disease indication remain undisclosed.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on TXP1-oligo2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXP1-oligo2.

Explore the full profile